Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CMIC Co, Ltd. Japan | INDUSTRY |
Not provided
Not provided
Not provided
The goal of this surveillance is to confirm the TBE device's safety and efficacy in patients treated with proximal landing in Zone 2 in the post-marketing period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TBE |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gore® TAG® Thoracic Aortic Branch Stent Graft System | Device | Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Device Technical Success at the Initial Procedure | All of the following must be met.
| Initial procedure |
| Aortic Rupture of the Treatment Lesion | Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan. | 60 Months |
| Lesion-related Mortality and All-cause Death | Lesion-related Mortality definition Deaths that meet any of the following criteria:
| 60 Months |
| Disable Stroke | Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: Persists for > 24 hours or until death | 60 Months |
| Serious Paraplegia | Paraplegia secondary to spinal cord ischemia reported as a serious adverse event from sites. | 60 Months |
| Serious Paraparesis |
Not provided
Not provided
Inclusion Criteria:
[Reference: Purpose of Use or Effects of TBE at the time of launch] The GORE TAG Thoracic Branch Endoprosthesis is intended for use in patients with the following diseases with descending thoracic aortic lesions who fulfill anatomical requirements for treatment of such diseases while preserving blood flow to the left subclavian artery.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hideyuki Saigusa | Contact | 819039126169 | hsaigusa@wlgore.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Osaka Hospital | Recruiting | Osaka | Suita | 565-0871 | Japan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017545 | Aortic Aneurysm, Thoracic |
| D000784 | Aortic Dissection |
| D014947 | Wounds and Injuries |
| ID | Term |
|---|---|
| D001014 | Aortic Aneurysm |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Paraparesis secondary to spinal cord ischemia reported as a serious adverse event from sites. |
| 60 Months |
| Renal Failure Requiring Dialysis | Renal failure reported as a serious adverse event by sites and confirmed to require dialysis. | 60 Months |
| Additional Unanticipated Post-procedural Surgical or Interventional Procedure | Additional unanticipated surgical procedure or endovascular procedure after the initial procedure. Anticipated or unanticipated status will be determined at the discretion of the investigator. Surgical procedures include conversion to thoracotomy, and endovascular procedures includes the placement of devices other than TBE. Endovascular procedures at the access site, lumbar drains for spinal cord ischemia, and procedures to address problems other than the treatment site (such as bare stent placement for intestinal ischemia due to dissection) do not apply. | 60 Months |
| Serious Device-related Ischemia | Ischemia reported by sites as a serious adverse event determined to be related to the device. | 60 Months |
| Distal Device-related Thromboembolic Serious Adverse Event Requiring Intervention or Surgery | Device-related ischemic adverse events reported by sites as serious adverse events that required bypass surgery, surgical procedures, or amputation, or that resulted in death. | 60 Months |
| Serious New Dissection | New events of arterial dissection reported as serious adverse events by sites. | 60 Months |
| Serious Myocardial Infarction | Myocardial infarction reported as a serious adverse event by the sites. | 60 Months |
| Serious Laryngeal or Phrenic Nerve Injury | Nerve damage events reported by the sites as serious adverse events that required retreatment. | 60 Months |
| Serious Heart Failure/Hypotension | Heart failure or hypotension reported as serious adverse events by the sites. | 60 Months |
| Aortic Enlargement in the Region Encompassed by the Initial Lesion | An increase of 5 mm or more in arterial diameter at the affected area compared to images taken at the first follow-up after initial treatment. | 60 Months |
| Endoleak | Serious adverse events reported or confirmed by imaging by the sites. The definitions of each type of endoleaks are as follows:
| 60 Months |
| Loss of Device Integrity | Defined as any of the following:
| 60 Months |
| Loss of Aortic or Aortic Branch Patency | No flow or contrast detected through the implanted aortic or side branch devices or distal CTAG devices after the index endovascular procedure. | 60 Months |
| Migration | Longitudinal movement of all or part of the device for a distance ≥10 mm, as confirmed by CT scan, relative to anatomical landmarks and device positioning at the first post-operative CT scan. | 60 Months |
| False Lumen Perfusion through the Primary Entry Tear (Dissection Patients only) | Flow from a proximal aortic source through the primary intimal tear into the aortic false lumen (similar to a Type IA endoleak after treatment of aneurysms). | 60 Months |
| Extension of a Dissection (Proximally or Distally) (Dissection Patients only) | Among the aortic dissections reported by sites as serious adverse events, those in which proximal or distal progression of the lesion from the initial procedure was confirmed on imaging. | 60 Months |
| False Lumen Status in Treated and Untreated Segments (Dissection Patients only) | The thrombosis state of the false lumen at the treated and untreated segments at the initial procedure is confirmed using the following three stages.
| 60 Months |
| D001018 |
| Aortic Diseases |
| D000094665 | Dissection, Blood Vessel |
| D000094683 | Acute Aortic Syndrome |